Effect of COVID-19 Pandemic on Anti-VEGF treatment of Medical Retinal Conditions – An Audit

Abstract

Introduction: Ophthalmology services have been significantly impacted by the COVID-19 pandemic. Frequency of intravitreal anti-vascular endothelial growth factor (Anti-VEGF) injections are important in visual outcomes.

Methods: We conducted an audit on intravitreal services in a NHS district general hospital in the UK including all new patients with diabetic macular oedema (CI-DMO) and wet age-related macular degeneration (AMD) who were initiated on intravitreal injection of Aflibercept (EYLEA) between 1st January to 15th July 2020, and had subsequent injections until October 2020. Data on injection dates and visual acuity was extracted, and the total number of all intravitreal injections for all indications between January to September 2020 and the same period in 2019. Delay to treatment was defined as more than 14 days, according to the fixed dosing schedule.

Results: We found 31% (n=17) of patients initiated on treatment for wet AMD and 44% (N=11) for CI-DMO had delayed injections. There was no correlation between total duration of delay and change in best corrected visual acuity (BCVA). Similarly, we found no association between duration of delay and change in BCVA. The number of intravitreal injections declined during the COVID-19 pandemic by 17.8% compared to 2019.

Conclusion: Majority of patients initiated on anti-VEGF injections just before the pandemic or during the pandemic received injections on time. Where there were significant delays to treatment, there was no detected loss in vision over the short term. However, the long-term impact and impact of overall reduction in intravitreal injections are unknown.

Keywords

Anti-vascular endothelial growth factor injections, intra-vitreal services, COVID-19 pandemic

Introduction:
The coronavirus disease 2019 (COVID-19) global pandemic affected the UK in March 2020. All routine hospital appointments and treatments were cancelled to prioritise resources towards treating COVID-19 infected patients. This significantly impacted practice in ophthalmology, dramatically reducing capacity within the hospital eye services. It has been paramount to weigh the risk of acquiring COVID-19 against the risk of coming to harm through failure to treat serious eye disease. Thus, for many patients,
hospital visits have been postponed to reduce exposure to the virus.

Anti-vascular endothelial growth factor (Anti-VEGF) intravitreal therapy has revolutionised the treatment of common causes of blindness including wet age-related macular degeneration (AMD) and centre involving diabetic macular oedema (CI-DMO). Notably, the frequency of intravitreal anti-VEGF injections has been shown to be an important contributing factor in improving and maintaining visual outcomes\textsuperscript{2–5} and delays have been shown to be associated with decreased vision\textsuperscript{6}. The current National Institute for Health and Care Excellence (NICE) recommendations for posology of aflibercept (EYLEA) are:

1. Wet AMD: one treatment per month for three consecutive doses, followed by one injection every two months up to twelve months\textsuperscript{7}
2. CI-DMO: one treatment per month for five consecutive doses, followed by one injection every two months up to twelve months\textsuperscript{8}

At our unit, we use a fixed regimen treatment protocol during year one, rather than a treat and extend (T&E). Therefore, during year one, wet AMD patients receive one injection per month for three consecutive doses followed by fixed two monthly injections up to twelve months, giving a total of seven injections. Using a T&E dosing regimen for wet AMD, patients also receive one injection per month for three consecutive doses then the treatment interval is extended to two months. However, based on the physician’s judgement, the treatment interval may be maintained at two months or further extended according to visual and/or anatomic outcomes\textsuperscript{9}.

In response to the COVID-19 pandemic, the Royal College of Ophthalmologists (RCOphth) published guidance to aid resource prioritisation and risk stratification\textsuperscript{10,11}. Regarding new patients, their guidance was to continue intravitreal injection (IVI) treatment for wet AMD (three monthly loading doses then fixed bimonthly IVI in year one). However, they advised that IVI treatment for patients with CI-DMO could be deferred by four to six months.

At our unit, we followed the RCOphth guidance with regards to wet AMD. However, given that our eye unit has a smaller cohort of CI-DMO patients compared to other larger centres, the decision was taken to continue to offer patients treatment provided they were happy to attend and understood the risks of COVID-19 transmission. Therefore, instead of deferring treatment, we continued to offer five loading doses followed by fixed bimonthly doses in year one and telephone consultations in year two and beyond.

The aim of this retrospective audit was to evaluate the impact of COVID-19 on IVI services at our unit; specifically, to assess whether patients who had IVI treatment initiated just before or during the pandemic had any delays to their fixed dosing treatment schedule. Where significant delays to treatment resulted, we evaluate whether there was any resulting loss in visual acuity. We also compare the total number of IVI for all indications in the period January to September 2020 to the equivalent period in 2019 to assess the overall impact of COVID-19 on the service.

**Methods:**

We conducted an Electronic Medical Records (EMR) audit evaluating the effects of the COVID-19 pandemic on intravitreal services at an NHS district general hospital in the UK. We used Medisoft audit suite tool to extract all patients who had initial (baseline) IVI treatment of wet AMD or CI-DMO with EYLEA between 1\textsuperscript{st} January to 15\textsuperscript{th} July 2020 and had subsequent follow up or injections until October 2020.

Data was manually extracted from Medisoft EMR for all visits up to 8\textsuperscript{th} October 2020, when analysis was commenced. Data collected included dates of IVI and best corrected visual acuity (BCVA) which was documented in the form of ETDRS (Early Treatment Diabetic Retinopathy Study) letter score. We also extracted total number of all IVI for all indications at our unit between January-September 2020 and the same period in 2019 for comparison.

Delay to treatment was defined as IVI given more than 14 days after it was scheduled to be given according to fixed dosing schedule. A delay of less than 14 days is not uncommon in clinical practice given the two-stop nature of the service.

P Values were calculated using Mann Whitney U Test to evaluate the statistical significance of the effect of delay on overall change in BCVA. Linear regression analysis was conducted to evaluate the relationship between delays to treatment and BCVA.

**Results:**

There were a total of 82 patients (88 eyes) of which 2 patients had deceased within 2 months of initiating treatment and were therefore excluded from analysis.
Of these, 55 patients (57 eyes) were treated for wet AMD and 25 patients (29 eyes) for CI-DMO.

We found that 69% of patients (n=38) receiving their first IVI for wet AMD between 1st January and 15th July 2020 had timely treatments whilst 31% (n=17) had a delay of more than 14 days from the fixed dosing schedule. Meanwhile, 56% (n=14) of patients receiving their first IVI for CI-DMO during this same period received timely treatment and 44% (N=11) had a delay of more than 14 days from the fixed dosing schedule (Fig.1).

**Figure 1.** A graph showing the percentage of patients who had a delay in treatment according to indication

Figure 2 illustrates the overall change in BCVA (most recent BCVA letter score minus baseline BCVA letter score) stratified according to whether there was a delay in treatment of the eye. In wet AMD, the mean change in BCVA (dotted line) was more negative for those with a delay to treatment (-1.33) than those without (+4.41) and the median change in BCVA was 0 and +5 respectively (P=0.19). In CI-DMO, the mean change in BCVA was more positive for those with a delay to treatment (+3.38) than those without (-2.50) and median change was +5 in both groups (P=0.51).
A total of 17 patients with wet AMD and 11 patients with C-DMO had a delay to treatment from the fixed dosing schedule. Of these, 5 patients with wet AMD and 3 patients with C-DMO had more than one delay period during their treatment. The mean, median and range of delays from the scheduled IVI treatment date are summarised in Table 1. Of those patients who had a delay to their treatment, 82% of these delays (N=14 wet AMD and N=9 C-DMO) were during the COVID-19 period (defined as 15th March to 15th July when there was the greatest disruption to services). There was no significant relationship between total delay (sum of individual delays per eye throughout the treatment course) and overall change in BCVA for either indication as shown by R² values (Figure 3).
Table 1: Table summarising the mean, median and range of delay from the fixed dosing schedule in days

<table>
<thead>
<tr>
<th>Delay (days)</th>
<th>AMD</th>
<th>DMO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>47</td>
<td>56</td>
</tr>
<tr>
<td>Median</td>
<td>26</td>
<td>31</td>
</tr>
<tr>
<td>Range</td>
<td>15-166</td>
<td>17-207</td>
</tr>
</tbody>
</table>

Wet AMD: 17 patients  
CI-DMO: 11 patients  

Figure 3. Relationship between total delay and overall change in BCVA in a. wet AMD ($R^2 = 0$) and b. CI-DMO ($R^2 = 0.21$, entirely dependent on data points at 137 days and 212 days)
Furthermore, there was no significant correlation between duration of delay in treatment between injections and change in BCVA between those same treatments as shown by the $R^2$ values of the linear regression models (Fig. 4). For AMD the change in treatment regimen from monthly to 8-weekly was considered in the analysis (Fig 4). For CI-DMO, there were no patients with delay in their treatment who had received more than the first five monthly injections therefore no change in treatment regimen was considered in analysis.

Figure 4. Relationship between delay in treatment and change in BCVA between these delayed treatments in a. AMD stratified according to first 3 monthly injections ($R^2 = 0$) and subsequent 8 weekly injections ($R^2 = 0.17$, entirely dependent on single point at 105 days) and b. CI-DMO first 5 monthly injections only ($R^2 = 0.06$)
Analysis of total injections for all indications between January-September 2020 compared to the same period in 2019 showed an overall decrease by 17.8% in injections at this eye unit. Fig. 5).

![Figure 5](image)

**Figure 5.** Comparison of the total number of anti-VEGF injections in the same period in 2019 and 2020 for all indications

**Discussion:**

Our results suggest that during the COVID-19 period the majority of wet AMD patients and many CI-DMO patients initiated on IVI treatment at our unit received treatments on time. However, there were fewer overall IVI at the department compared to same period in 2019, including new and follow up patients.

We found no significant correlation between the total duration of delay and overall change in BCVA over the treatment period. We also found no association between treatment delay between subsequent injections and change in BCVA between these same treatments.

There was marginal loss of vision (p=0.19) in wet AMD due to delay, however CI-DMO patients who had a delay to treatment had a relative improvement in BCVA (p=0.50). In both cases, these changes in BCVA were not statistically significant. However, it is plausible that delay in treatment of CI-DMO may not significantly affect BCVA due to the more indolent nature of maculopathy. Delay in treatment was also found not to affect final BCVA outcomes in the recent DRCR.net Protocol V study12.

The approach to the pandemic has been variable, with some eye units maintaining IVI injections even through the height of the pandemic13 and other units experiencing a significant drop in their IVI services14,15. There is still limited literature evaluating the impact of delays to IVI treatment during COVID-19 on visual outcomes and to our knowledge, there is no study looking at patients initiated on IVI treatment during or just prior to the pandemic.

One study in Northern Italy evaluated the impact of delays secondary to COVID-19 on maintenance IVI treatment of wet AMD. They found a significant association between interval time between treatments and BCVA in wet AMD patients who were established on a PRN approach prior to the pandemic16.

Given that the COVID-19 pandemic and its impact on ophthalmology services is ongoing, it is important to evaluate the risk of short- and long-term vision loss associated with extending intervals between treatments against the prevalence of COVID-19 in community and individual patient comorbidities.

**Limitations and considerations:**

Our analysis of the effect of delays in IVI treatment on BCVA was limited as the majority of our patients did not have a delay to treatment. Furthermore, our follow up was limited to nine months, but it would be important to consider the longer-term effects of delays to IVI treatment. We therefore intend to conduct a follow up study to assess the longer-term effects of these delays on visual outcomes of these patients.

**References:**


**Conflicts of interest:**

Dr Mana Rahimzadeh, Foundation Year Two Doctor: No conflicts of interest

Mr Ramu Muniraju, Consultant Ophthalmologist with special interest in medical retina: Received travel grants and hospitality to attend educational meetings from Allergan and Bayer

Miss Shahrnaz Izadi, Consultant Ophthalmologist with a special interest in medical retina: Received travel grants and hospitality to attend educational meetings from Novartis